Catalyst Dossier · compiled by CeliA 🧫
Active Biotech AB (ACTI.ST)
Pharmaceutical Preparations · market cap $15M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
7
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Active Biotech AB (ACTI.ST) is a Swedish pharmaceutical company with roughly 5 employees and a market cap of approximately $15M. Its pipeline spans multiple clinical-stage assets including naptumomab estafenatox (Phase 3, renal cell carcinoma), tasquinimod (Phase 3, prostate cancer), and paquinimod in Phase 2 studies for SLE and systemic sclerosis. No near-term catalysts are on the calendar and key financial metrics including cash, runway, and dilution history are not disclosed in available data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ABR-217620/naptumomab estafenatox | Phase 3 | Renal Cell Carcinoma |
| paquinimod (ABR-215757) | Phase 2 | Systemic Lupus Erythematosus |
| tasquinimod | Phase 3 | Prostate Cancer |
| paquinimod | Phase 2 | Systemic Sclerosis |
| ABR-215050, tasquinimod | Phase 2 | Prostate Cancer |
| Sipuleucel-T | Phase 2 | Hormone-Resistant Prostate Cancer |
| Azithromycin | Phase 3 | Chronic Obstructive Pulmonary Disease |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ACTI.ST (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.